APOLLO Trial Finds Experimental ‘Gene Silencing’ Therapy Reduces Lipoprotein(a) By Up To 98%

Presented at ACC as a Late-Breaking Clinical Trial, the Cleveland Clinic-led APOLLO trial explores siRNA therapy as a treatment option to help prevent premature heart disease in people with high levels of Lp(a). This condition is estimated to affect 64 million people in the United States and 1.4 billion people worldwide. It is estimated that nearly 20 to 25% of the world’s population has elevated Lp(a). Dr. Steven Nissen, M.D., Chief Academic Officer of the Heart, Vascular & Thoracic Institute at Cleveland Clinic explains the purpose, patient selection, and findings of APOLLO. Learn more about Dr. Steven Nissen https://my.clevelandclinic.org/staff/1185-steven-nissen#biography See the ConsultQD article here https://consultqd.clevelandclinic.org/novel-sirna-therapy-lowers-elevated-plasma-lipoproteina-in-phase-1-apollo-trial/ See the Cleveland Clinic News Release here https://newsroom.clevelandclinic.org/2022/04/03/cleveland-clinic-led-trial-finds-that-experimental-gene-silencing-therapy-reduces-lipoproteina-an-important-risk-factor-of-heart-disease-by-up-to-98/ See the full article https://jamanetwork.com/journals/jama/fullarticle/2790912 Nissen SE, Wolski K, Balog C, et al. Single Ascending Dose Study of a Short Interfering RNA Targeting Lipoprotein(a) Production in Individuals With Elevated Plasma Lipoprotein(a) Levels. JAMA. Published online April 03, 2022. doi:10.1001/jama.2022.5050